Oncogenesis
@oncogenesisnature.bsky.social
December 11, 2025 at 10:07 AM
Check how their results provide experimental evidence to distinguish BCL2 transmembrane driver mutations from passenger mutations and provide new insight regarding selecting precision anti-tumor treatments.
December 11, 2025 at 10:07 AM
Check how their results provide experimental evidence to distinguish BCL2 transmembrane driver mutations from passenger mutations and provide new insight regarding selecting precision anti-tumor treatments.
December 9, 2025 at 9:15 AM
Check how overexpression of YTHDF3 in breast cancer cells upregulates the expression of ZEB1 and SMAD5, which promotes the EMT process, increasing the invasiveness of breast cancer cells. Take a closer look at the mechanism the authors propose.
December 9, 2025 at 9:14 AM
Check how overexpression of YTHDF3 in breast cancer cells upregulates the expression of ZEB1 and SMAD5, which promotes the EMT process, increasing the invasiveness of breast cancer cells. Take a closer look at the mechanism the authors propose.
December 5, 2025 at 9:28 AM
With that vision, I have joined Oncogenesis as an Associate Editor, committed to supporting a platform where impactful cancer research can flourish and inspire.
Lab website: www.ssshen.com
Delighted to have him on our team at Oncogenesis! 🤝
Lab website: www.ssshen.com
Delighted to have him on our team at Oncogenesis! 🤝
December 5, 2025 at 9:27 AM
With that vision, I have joined Oncogenesis as an Associate Editor, committed to supporting a platform where impactful cancer research can flourish and inspire.
Lab website: www.ssshen.com
Delighted to have him on our team at Oncogenesis! 🤝
Lab website: www.ssshen.com
Delighted to have him on our team at Oncogenesis! 🤝
Science advances not only through discovery, but through dialogue—rigorous, transparent, and meaningful exchange across disciplines and borders.
As the pace of innovation accelerates, so too must our responsibility to uphold the standards that give research its lasting value.
As the pace of innovation accelerates, so too must our responsibility to uphold the standards that give research its lasting value.
December 5, 2025 at 9:26 AM
Science advances not only through discovery, but through dialogue—rigorous, transparent, and meaningful exchange across disciplines and borders.
As the pace of innovation accelerates, so too must our responsibility to uphold the standards that give research its lasting value.
As the pace of innovation accelerates, so too must our responsibility to uphold the standards that give research its lasting value.
By uncovering the biology of drug-tolerant persister cells, we aim to shift the therapeutic lens from simply targeting bulk tumor populations to confronting the elusive reservoirs of relapse.
December 5, 2025 at 9:26 AM
By uncovering the biology of drug-tolerant persister cells, we aim to shift the therapeutic lens from simply targeting bulk tumor populations to confronting the elusive reservoirs of relapse.
We focus on how melanoma and small cell lung carcinoma escape standard-of-care therapies through non-genetic, reversible states of persistence.
December 5, 2025 at 9:26 AM
We focus on how melanoma and small cell lung carcinoma escape standard-of-care therapies through non-genetic, reversible states of persistence.
December 2, 2025 at 8:15 AM
Check how ACSL6, by modulating key metabolic and signaling pathways, could influence cellular susceptibility to ferroptosis and may guide therapeutic approaches that enhance chemotherapy through DHA supplementation.
December 2, 2025 at 8:15 AM
Check how ACSL6, by modulating key metabolic and signaling pathways, could influence cellular susceptibility to ferroptosis and may guide therapeutic approaches that enhance chemotherapy through DHA supplementation.
November 27, 2025 at 10:03 AM
Check how their findings suggest that P4HB could serve not only as a potential therapeutic target for glioblastoma but also as a biomarker for auxiliary diagnosis and monitoring of disease progression.
November 27, 2025 at 10:03 AM
Check how their findings suggest that P4HB could serve not only as a potential therapeutic target for glioblastoma but also as a biomarker for auxiliary diagnosis and monitoring of disease progression.
November 25, 2025 at 11:05 AM
Check how PANX1 triggers rhabdomyosarcoma cell fusion by downregulating APOBEC2 expression, forcing these undifferentiated malignant cells further into the myogenic pathway, offering therapeutic potential by limiting malignant progression.
November 25, 2025 at 11:05 AM
Check how PANX1 triggers rhabdomyosarcoma cell fusion by downregulating APOBEC2 expression, forcing these undifferentiated malignant cells further into the myogenic pathway, offering therapeutic potential by limiting malignant progression.
November 20, 2025 at 8:21 AM
Check how this study provides novel mechanistic insights into the role of LUBAC in regulating HIF1α homeostasis, tumor angiogenesis and tumorigenesis of lung cancer, making LUBAC an attractive therapeutic target for cancers.
November 20, 2025 at 8:21 AM
Check how this study provides novel mechanistic insights into the role of LUBAC in regulating HIF1α homeostasis, tumor angiogenesis and tumorigenesis of lung cancer, making LUBAC an attractive therapeutic target for cancers.
November 18, 2025 at 9:30 AM